Pathogenesis of Gout

Reviews4 October 2005Pathogenesis of GoutHyon K. Choi, MD, DrPH, David B. Mount, MD, and Anthony M. Reginato, MD, PhDHyon K. Choi, MD, DrPHFrom Arthritis Research Centre of Canada, University of British Columbia, Vancouver, British Columbia, Canada; Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, and VA Boston Healthcare System, Boston, Massachusetts.Search for more papers by this author, David B. Mount, MDFrom Arthritis Research Centre of Canada, University of British Columbia, Vancouver, British Columbia, Canada; Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, and VA Boston Healthcare System, Boston, Massachusetts.Search for more papers by this author, and Anthony M. Reginato, MD, PhDFrom Arthritis Research Centre of Canada, University of British Columbia, Vancouver, British Columbia, Canada; Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, and VA Boston Healthcare System, Boston, Massachusetts.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-7-200510040-00009 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Clinical PrinciplesThe overall disease burden of gout is substantial and may be increasing.As more scientific data on the modifiable risk factors and comorbidities of gout become available, integration of these data into gout care strategies may become essential.Hyperuricemia and gout are associated with the insulin resistance syndrome and related comorbid conditions.Lifestyle modifications that are recommended for gout generally align with those for major chronic disorders (such as the insulin resistance syndrome, hypertension, and cardiovascular disorders); thus, these measures may be doubly beneficial for many patients with gout and particularly for individuals with these comorbid conditions.Effective management of risk factors for ...References1. Terkeltaub RA. Clinical practice. Gout. N Engl J Med. 2003;349:1647-55. [PMID: 14573737] CrossrefMedlineGoogle Scholar2. Schlesinger N, Schumacher HR. Gout: can management be improved? Curr Opin Rheumatol. 2001;13:240-4. [PMID: 11333356] CrossrefMedlineGoogle Scholar3. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis. 2002;40:37-42. [PMID: 12087559] CrossrefMedlineGoogle Scholar4. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 2002;29:2403-6. [PMID: 12415600] MedlineGoogle Scholar5. Johnson RJ, Rideout BA. Uric acid and diet—insights into the epidemic of cardiovascular disease. N Engl J Med. 2004;350:1071-3. [PMID: 15014177] CrossrefMedlineGoogle Scholar6. Wu XW, Lee CC, Muzny DM, Caskey CT. Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci U S A. 1989;86:9412-6. [PMID: 2594778] CrossrefMedlineGoogle Scholar7. Wu XW, Muzny DM, Lee CC, Caskey CT. Two independent mutational events in the loss of urate oxidase during hominoid evolution. J Mol Evol. 1992;34:78-84. [PMID: 1556746] CrossrefMedlineGoogle Scholar8. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78:6858-62. [PMID: 6947260] CrossrefMedlineGoogle Scholar9. Hediger MA. Kidney function: gateway to a long life? Nature. 2002;417:393, 395. [PMID: 12024201] CrossrefMedlineGoogle Scholar10. Oda M, Satta Y, Takenaka O, Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol. 2002;19:640-53. [PMID: 11961098] CrossrefMedlineGoogle Scholar11. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension. 2002;40:355-60. [PMID: 12215479] CrossrefMedlineGoogle Scholar12. Oparil S, Zaman MA, Calhoun DA. Pathogenesis of hypertension. Ann Intern Med. 2003;139:761-76. [PMID: 14597461] LinkGoogle Scholar13. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421-6. [PMID: 3826098] CrossrefMedlineGoogle Scholar14. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol. 2000;27:1501-5. [PMID: 10852278] MedlineGoogle Scholar15. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51:321-5. [PMID: 15188314] CrossrefMedlineGoogle Scholar16. Burt HM, Dutt YC. Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates. Ann Rheum Dis. 1986;45:858-64. [PMID: 3098195] CrossrefMedlineGoogle Scholar17. McGill NW, Dieppe PA. The role of serum and synovial fluid components in the promotion of urate crystal formation. J Rheumatol. 1991;18:1042-5. [PMID: 1717687] MedlineGoogle Scholar18. Fam AG, Stein J, Rubenstein J. Gouty arthritis in nodal osteoarthritis. J Rheumatol. 1996;23:684-9. [PMID: 8730127] MedlineGoogle Scholar19. Simkin PA, Pizzorno JE. Transynovial exchange of small molecules in normal human subjects. J Appl Physiol. 1974;36:581-7. [PMID: 4826322] CrossrefMedlineGoogle Scholar20. Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman M. Rheumatology. 3rd ed. New York: Mosby; 2003. Google Scholar21. Griebsch A, Zollner N. Effect of ribomononucleotides given orally on uric acid production in man. Adv Exp Med Biol. 1974;41:443-9. [PMID: 4832569] CrossrefMedlineGoogle Scholar22. Coe FL, Moran E, Kavalich AG. The contribution of dietary purine over-consumption to hyperpuricosuria in calcium oxalate stone formers. J Chronic Dis. 1976;29:793-800. [PMID: 1010873] CrossrefMedlineGoogle Scholar23. Gibson T, Rodgers AV, Simmonds HA, Court-Brown F, Todd E, Meilton V. A controlled study of diet in patients with gout. Ann Rheum Dis. 1983;42:123-7. [PMID: 6847259] CrossrefMedlineGoogle Scholar24. Zollner N, Griebsch A. Diet and gout. Adv Exp Med Biol. 1974;41:435-42. [PMID: 4832568] CrossrefMedlineGoogle Scholar25. Clifford AJ, Riumallo JA, Young VR, Scrimshaw NS. Effects of oral purines on serum and urinary uric acid of normal, hyperuricaemic and gouty humans [Abstract]. J Nutr. 1976;106:428-50. CrossrefGoogle Scholar26. Watson AR, Simmonds HA, Webster DR, Layward L, Evans DI. Purine nucleoside phosphorylase (PNP) deficiency: a therapeutic challenge. Adv Exp Med Biol. 1984;165 Pt A 53-9. [PMID: 6426259] CrossrefMedlineGoogle Scholar27. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093-103. [PMID: 15014182] CrossrefMedlineGoogle Scholar28. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the Health Professionals Follow-up Study. Arch Intern Med. 2005;165:742-8. [PMID: 15824292] CrossrefMedlineGoogle Scholar29. Emmerson BT. The management of gout. N Engl J Med. 1996;334:445-51. [PMID: 8552148] CrossrefMedlineGoogle Scholar30. Fam AG. Gout, diet, and the insulin resistance syndrome [Editorial]. J Rheumatol. 2002;29:1350-5. [PMID: 12136887] MedlineGoogle Scholar31. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet. 2004;363:1277-81. [PMID: 15094272] CrossrefMedlineGoogle Scholar32. Willett WC, Stampfer MJ. Rebuilding the food pyramid. Sci Am. 2003;288:64-71. [PMID: 12506426] CrossrefMedlineGoogle Scholar33. Klippel JH. Primer on the Rheumatic Diseases. 12th ed. Atlanta, GA: Arthritis Foundation; 2001. Google Scholar34. Koopman WJ. Arthritis & Allied Conditions: A Textbook of Rheumatology. 12th ed. New York: Lippincott Williams & Wilkins; 2001. Google Scholar35. Woolliscroft JO, Colfer H, Fox IH. Hyperuricemia in acute illness: a poor prognostic sign. Am J Med. 1982;72:58-62. [PMID: 7058824] CrossrefMedlineGoogle Scholar36. Woolliscroft JO, Fox IH. Increased body fluid purine levels during hypotensive events. Evidence for ATP degradation. Am J Med. 1986;81:472-8. [PMID: 3752148] CrossrefMedlineGoogle Scholar37. Mineo I, Kono N, Hara N, Shimizu T, Yamada Y, Kawachi M, et al. Myogenic hyperuricemia. A common pathophysiologic feature of glycogenosis types III, V, and VII. N Engl J Med. 1987;317:75-80. [PMID: 3473284] CrossrefMedlineGoogle Scholar38. Fox IH. Adenosine triphosphate degradation in specific disease. J Lab Clin Med. 1985;106:101-10. [PMID: 3860585] MedlineGoogle Scholar39. Jinnai K, Kono N, Yamamoto Y, Kanda F, Ohno S, Tsutsumi M, et al. Glycogenosis type V (McArdle's disease) with hyperuricemia. A case report and clinical investigation. Eur Neurol. 1993;33:204-7. [PMID: 8467838] CrossrefMedlineGoogle Scholar40. Yamanaka H, Kawagoe Y, Taniguchi A, Kaneko N, Kimata S, Hosoda S, et al. Accelerated purine nucleotide degradation by anaerobic but not by aerobic ergometer muscle exercise. Metabolism. 1992;41:364-9. [PMID: 1556942] CrossrefMedlineGoogle Scholar41. Faller J, Fox IH. Ethanol-induced hyperuricemia: evidence for increased urate production by activation of adenine nucleotide turnover. N Engl J Med. 1982;307:1598-602. [PMID: 7144847] CrossrefMedlineGoogle Scholar42. Fox IH, Kelley WN. Studies on the mechanism of fructose-induced hyperuricemia in man. Metabolism. 1972;21:713-21. [PMID: 5047915] CrossrefMedlineGoogle Scholar43. Raivio KO, Becker A, Meyer LJ, Greene ML, Nuki G, Seegmiller JE. Stimulation of human purine synthesis de novo by fructose infusion. Metabolism. 1975;24:861-9. [PMID: 166270] CrossrefMedlineGoogle Scholar44. Puig JG, Fox IH. Ethanol-induced activation of adenine nucleotide turnover. Evidence for a role of acetate. J Clin Invest. 1984;74:936-41. [PMID: 6470146] CrossrefMedlineGoogle Scholar45. Lieber CS, Jones DP, Losowsky MS, Davidson CS. Interrelation of uric acid and ethanol metabolism in man. J Clin Invest. 1962;41:1863-70. [PMID: 13930523] CrossrefMedlineGoogle Scholar46. Choi HK, Curhan G. Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2004;51:1023-9. [PMID: 15593346] CrossrefMedlineGoogle Scholar47. Gibson T, Rodgers AV, Simmonds HA, Toseland P. Beer drinking and its effect on uric acid. Br J Rheumatol. 1984;23:203-9. [PMID: 6743968] CrossrefMedlineGoogle Scholar48. Fox IH, Palella TD, Kelley WN. Hyperuricemia: a marker for cell energy crisis [Editorial]. N Engl J Med. 1987;317:111-2. [PMID: 3473283] CrossrefMedlineGoogle Scholar49. Emmerson BT. Effect of oral fructose on urate production. Ann Rheum Dis. 1974;33:276-80. [PMID: 4843132] CrossrefMedlineGoogle Scholar50. Stirpe F, Della Corte E, Bonetti E, Abbondanza A, Abbati A, De Stefano F. Fructose-induced hyperuricaemia. Lancet. 1970;2:1310-1. [PMID: 4098798] CrossrefMedlineGoogle Scholar51. Gross LS, Li L, Ford ES, Liu S. Increased consumption of refined carbohydrates and the epidemic of type 2 diabetes in the United States: an ecologic assessment. Am J Clin Nutr. 2004;79:774-9. [PMID: 15113714] CrossrefMedlineGoogle Scholar52. Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr. 2004;79:537-43. [PMID: 15051594] CrossrefMedlineGoogle Scholar53. Glynn RJ, Campion EW, Silbert JE. Trends in serum uric acid levels 1961-1980. Arthritis Rheum. 1983;26:87-93. [PMID: 6824508] CrossrefMedlineGoogle Scholar54. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis. 1998;57:509-10. [PMID: 9849306] CrossrefMedlineGoogle Scholar55. Lee J, Sparrow D, Vokonas PS, Landsberg L, Weiss ST. Uric acid and coronary heart disease risk: evidence for a role of uric acid in the obesity-insulin resistance syndrome. The Normative Aging Study. Am J Epidemiol. 1995;142:288-94. [PMID: 7631632] CrossrefMedlineGoogle Scholar56. Rathmann W, Funkhouser E, Dyer AR, Roseman JM. Relations of hyperuricemia with the various components of the insulin resistance syndrome in young black and white adults: the CARDIA study. Coronary Artery Risk Development in Young Adults. Ann Epidemiol. 1998;8:250-61. [PMID: 9590604] CrossrefMedlineGoogle Scholar57. Roubenoff R, Klag MJ, Mead LA, Liang KY, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. JAMA. 1991;266:3004-7. [PMID: 1820473] CrossrefMedlineGoogle Scholar58. Dessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59:539-43. [PMID: 10873964] CrossrefMedlineGoogle Scholar59. Yamashita S, Matsuzawa Y, Tokunaga K, Fujioka S, Tarui S. Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. Int J Obes. 1986;10:255-64. [PMID: 3771090] MedlineGoogle Scholar60. Emmerson BT. Alteration of urate metabolism by weight reduction. Aust N Z J Med. 1973;3:410-2. [PMID: 4519128] CrossrefMedlineGoogle Scholar61. Ter Maaten JC, Voorburg A, Heine RJ, Ter Wee PM, Donker AJ, Gans RO. Renal handling of urate and sodium during acute physiological hyperinsulinaemia in healthy subjects. Clin Sci (Lond). 1997;92:51-8. [PMID: 9038591] CrossrefMedlineGoogle Scholar62. Muscelli E, Natali A, Bianchi S, Bigazzi R, Galvan AQ, Sironi AM, et al. Effect of insulin on renal sodium and uric acid handling in essential hypertension. Am J Hypertens. 1996;9:746-52. [PMID: 8862220] CrossrefMedlineGoogle Scholar63. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447-52. [PMID: 12024214] CrossrefMedlineGoogle Scholar64. Bedir A, Topbas M, Tanyeri F, Alvur M, Arik N. Leptin might be a regulator of serum uric acid concentrations in humans. Jpn Heart J. 2003;44:527-36. [PMID: 12906034] CrossrefMedlineGoogle Scholar65. Fruehwald-Schultes B, Peters A, Kern W, Beyer J, Pfutzner A. Serum leptin is associated with serum uric acid concentrations in humans. Metabolism. 1999;48:677-80. [PMID: 10381138] CrossrefMedlineGoogle Scholar66. Bakker SJ, Gans RO, ter Maaten JC, Teerlink T, Westerhoff HV, Heine RJ. The potential role of adenosine in the pathophysiology of the insulin resistance syndrome. Atherosclerosis. 2001;155:283-90. [PMID: 11254897] CrossrefMedlineGoogle Scholar67. Balakrishnan VS, Coles GA, Williams JD. Effects of intravenous adenosine on renal function in healthy human subjects. Am J Physiol. 1996;271:F374-81. [PMID: 8770169] MedlineGoogle Scholar68. Balakrishnan VS, Coles GA, Williams JD. A potential role for endogenous adenosine in control of human glomerular and tubular function. Am J Physiol. 1993;265:F504-10. [PMID: 8238379] MedlineGoogle Scholar69. Fransen R, Koomans HA. Adenosine and renal sodium handling: direct natriuresis and renal nerve-mediated antinatriuresis. J Am Soc Nephrol. 1995;6:1491-7. [PMID: 8589328] CrossrefMedlineGoogle Scholar70. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-7. [PMID: 12365955] CrossrefMedlineGoogle Scholar71. Freedman DS, Khan LK, Serdula MK, Galuska DA, Dietz WH. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA. 2002;288:1758-61. [PMID: 12365960] CrossrefMedlineGoogle Scholar72. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287:356-9. [PMID: 11790215] CrossrefMedlineGoogle Scholar73. Wyngaarden JB, Kelley WN. Gout and Hyperuricemia. New York: Grune & Stratton; 1976. Google Scholar74. Prebis JW, Gruskin AB, Polinsky MS, Baluarte HJ. Uric acid in childhood essential hypertension. J Pediatr. 1981;98:702-7. [PMID: 7229748] CrossrefMedlineGoogle Scholar75. Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med. 1980;93:817-21. [PMID: 7447188] LinkGoogle Scholar76. Diamond HS, Paolino JS. Evidence for a postsecretory reabsorptive site for uric acid in man. J Clin Invest. 1973;52:1491-9. [PMID: 4703233] CrossrefMedlineGoogle Scholar77. Giebisch G, Windhager E. Transport of urea, glucose, phosphate, calcium, magnesium, and organic solutes.. In: Boron W, Boulpaep E, eds. Medical Physiology. Philadelphia: WB Saunders; 2003:790-813. Google Scholar78. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43:103-8. [PMID: 10643705] CrossrefMedlineGoogle Scholar79. Steele TH. Evidence for altered renal urate reabsorption during changes in volume of the extracellular fluid. J Lab Clin Med. 1969;74:288-99. [PMID: 5799512] MedlineGoogle Scholar80. Steele TH, Oppenheimer S. Factors affecting urate excretion following diuretic administration in man. Am J Med. 1969;47:564-74. [PMID: 4309843] CrossrefMedlineGoogle Scholar81. Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989;321:287-92. [PMID: 2664517] CrossrefMedlineGoogle Scholar82. Gupta AK, Rocher LL, Schmaltz SP, Goldfarb MT, Brown MD, Ellis CN, et al. Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders. Arch Intern Med. 1991;151:356-62. [PMID: 1992963] CrossrefMedlineGoogle Scholar83. Hansen JM, Fogh-Andersen N, Leyssac PP, Strandgaard S. Glomerular and tubular function in renal transplant patients treated with and without ciclosporin A. Nephron. 1998;80:450-7. [PMID: 9832645] CrossrefMedlineGoogle Scholar84. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol. 2000;11:974-9. [PMID: 10770978] CrossrefMedlineGoogle Scholar85. Ahn KJ, Kim YS, Lee HC, Park K, Huh KB. Cyclosporine-induced hyperuricemia after renal transplant: clinical characteristics and mechanisms. Transplant Proc. 1992;24:1391-2. [PMID: 1496597] MedlineGoogle Scholar86. Chanard J, Toupance O, Lavaud S, Hurault de Ligny B, Bernaud C, Moulin B. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant. 2003;18:2147-53. [PMID: 13679494] CrossrefMedlineGoogle Scholar87. Starzl TE, Fung J, Jordan M, Shapiro R, Tzakis A, McCauley J, et al. Kidney transplantation under FK 506. JAMA. 1990;264:63-7. [PMID: 1693970] CrossrefMedlineGoogle Scholar88. Boots JM, van Duijnhoven EM, Christiaans MH, Nieman FH, van Suylen RJ, van Hooff JP. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int. 2001;14:370-83. [PMID: 11793034] CrossrefMedlineGoogle Scholar89. Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther. 2003;17:397-414. [PMID: 15107595] CrossrefMedlineGoogle Scholar90. Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan—influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol. 2004;15:164-73. [PMID: 14694169] CrossrefMedlineGoogle Scholar91. Roch-Ramel F, Guisan B. Renal transport of urate in humans. News Physiol Sci. 1999;14:80-84. [PMID: 11390825] MedlineGoogle Scholar92. Simmonds HA, Hatfield PJ, Cameron JS, Cadenhead A. Uric acid excretion by the pig kidney. Am J Physiol. 1976;230:1654-61. [PMID: 7142] CrossrefMedlineGoogle Scholar93. Guggino SE, Aronson PS. Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes. J Clin Invest. 1985;76:543-7. [PMID: 4031062] CrossrefMedlineGoogle Scholar94. Roch-Ramel F, Guisan B, Schild L. Indirect coupling of urate and p-amino hippurate transport to sodium in human brush-border membrane vesicles. Am J Physiol. 1996;270:F61-8. [PMID: 8769823] MedlineGoogle Scholar95. Padova J, Bendersky G. Hyperuricemia in diabetic ketoacidosis. N Engl J Med. 1962;267:530-4. [PMID: 14483098] CrossrefMedlineGoogle Scholar96. Gershon SL, Fox IH. Pharmacologic effects of nicotinic acid on human purine metabolism. J Lab Clin Med. 1974;84:179-86. [PMID: 4367231] MedlineGoogle Scholar97. Blomstedt JW, Aronson PS. pH gradient-stimulated transport of urate and p-amino hippurate in dog renal microvillus membrane vesicles. J Clin Invest. 1980;65:931-4. [PMID: 7358852] CrossrefMedlineGoogle Scholar98. Guggino SE, Martin GJ, Aronson PS. Specificity and modes of the anion exchanger in dog renal microvillus membranes. Am J Physiol. 1983;244:F612-21. [PMID: 6859253] MedlineGoogle Scholar99. Kahn AM, Aronson PS. Urate transport via anion exchange in dog renal microvillus membrane vesicles. Am J Physiol. 1983;244:F56-63. [PMID: 6849384] MedlineGoogle Scholar100. Kahn AM, Branham S, Weinman EJ. Mechanism of urate and p-aminohippurate transport in rat renal microvillus membrane vesicles. Am J Physiol. 1983;245:F151-8. [PMID: 6309010] MedlineGoogle Scholar101. Roch-Ramel F, Werner D, Guisan B. Urate transport in brush-border membrane of human kidney. Am J Physiol. 1994;266:F797-805. [PMID: 8203564] MedlineGoogle Scholar102. Garcia ML, Benavides J, Valdivieso F. Ketone body transport in renal brush border membrane vesicles. Biochim Biophys Acta. 1980;600:922-30. [PMID: 7407151] CrossrefMedlineGoogle Scholar103. Manganel M, Roch-Ramel F, Murer H. Sodium-pyrazinoate cotransport in rabbit renal brush border membrane vesicles. Am J Physiol. 1985;249:F400-8. [PMID: 4037092] MedlineGoogle Scholar104. Boumendil-Podevin EF, Podevin RA. Nicotinic acid transport by brush border membrane vesicles from rabbit kidney. Am J Physiol. 1981;240:F185-91. [PMID: 7212065] MedlineGoogle Scholar105. Coady MJ, Chang MH, Charron FM, Plata C, Wallendorff B, Sah JF, et al. The human tumour suppressor gene SLC5A8 expresses a Na+-monocarboxylate cotransporter. J Physiol. 2004;557:719-31. [PMID: 15090606] CrossrefMedlineGoogle Scholar106. Zandi-Nejad K, Plata C, Enck AH, Mercado A, Romero MF, Mount DB. Slc5a8 functions as a sodium-dependent pyrazinoate and nicotinate cotransporter; implications for renal urate transport. J Am Soc Nephrol. 2004;15:89A. Google Scholar107. Weinman EJ, Eknoyan G, Suki WN. The influence of the extracellular fluid volume on the tubular reabsorption of uric acid. J Clin Invest. 1975;55:283-91. [PMID: 1127100] CrossrefMedlineGoogle Scholar108. Ferris TF, Gorden P. Effect of angiotensin and norepinephrine upon urate clearance in man. Am J Med. 1968;44:359-65. [PMID: 4295950] CrossrefMedlineGoogle Scholar109. Moriwaki Y, Yamamoto T, Tsutsumi Z, Takahashi S, Hada T. Effects of angiotensin II infusion on renal excretion of purine bases and oxypurinol. Metabolism. 2002;51:893-5. [PMID: 12077737] CrossrefMedlineGoogle Scholar110. Quinones Galvan A, Natali A, Baldi S, Frascerra S, Sanna G, Ciociaro D, et al. Effect of insulin on uric acid excretion in humans. Am J Physiol. 1995;268:1-5. [PMID: 7840165] MedlineGoogle Scholar111. Mintz DH, Canary JJ, Carreon G, Kyle LH. Hyperuricemia in hyperparathyroidism. N Engl J Med. 1961;265:112-5. [PMID: 13771118] CrossrefMedlineGoogle Scholar112. Kahn AM, Weinman EJ. Urate transport in the proximal tubule: in vivo and vesicle studies. Am J Physiol. 1985;249:F789-98. [PMID: 3000189] MedlineGoogle Scholar113. Fanelli GM, Weiner IM. Pyrazinoate excretion in the chimpanzee. Relation to urate disposition and the actions of uricosuric drugs. J Clin Invest. 1973;52:1946-57. [PMID: 4719671] CrossrefMedlineGoogle Scholar114. Steele TH. Hyperuricemic nephropathies. Nephron. 1999;81 Suppl 1 45-9. [PMID: 9873214] CrossrefMedlineGoogle Scholar115. Yu TF, Gutman AB. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest. 1959;38:1298-315. [PMID: 13673086] CrossrefMedlineGoogle Scholar116. Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles. J Pharmacol Exp Ther. 1997;280:839-45. [PMID: 9023298] MedlineGoogle Scholar117. Kahn AM, Shelat H, Weinman EJ. Urate and p-aminohippurate transport in rat renal basolateral vesicles. Am J Physiol. 1985;249:F654-61. [PMID: 4061653] MedlineGoogle Scholar118. Werner D, Roch-Ramel F. Indirect Na+ dependency of urate and p-aminohippurate transport in pig basolateral membrane vesicles. Am J Physiol. 1991;261:F265-72. [PMID: 1877650] MedlineGoogle Scholar119. Ichida K, Hosoyamada M, Kimura H, Takeda M, Utsunomiya Y, Hosoya T, et al. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int. 2003;63:143-55. [PMID: 12472777] CrossrefMedlineGoogle Scholar120. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001;59:1277-86. [PMID: 11306713] CrossrefMedlineGoogle Scholar121. Bakhiya A, Bahn A, Burckhardt G, Wolff N. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem. 2003;13:249-56. [PMID: 14586168] CrossrefMedlineGoogle Scholar122. Sweet DH, Chan LM, Walden R, Yang XP, Miller DS, Pritchard JB. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient. Am J Physiol Renal Physiol. 2003;284:F763-9. [PMID: 12488248] CrossrefMedlineGoogle Scholar123. Aslamkhan A, Han YH, Walden R, Sweet DH, Pritchard JB. Stoichiometry of organic anion/dicarboxylate exchange in membrane vesicles from rat renal cortex and hOAT1-expressing cells. Am J Physiol Renal Physiol. 2003;285:F775-83. [PMID: 12837685] CrossrefMedlineGoogle Scholar124. Lipkowitz MS, Leal-Pinto E, Rappoport JZ, Najfeld V, Abramson RG. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest. 2001;107:1103-15. [PMID: 11342574] CrossrefMedlineGoogle Scholar125. Jutabha P, Kanai Y, Hosoyamada M, Chairoungdua A, Kim do K, Iribe Y, et al. Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule. J Biol Chem. 2003;278:27930-8. [PMID: 12740363] CrossrefMedlineGoogle Scholar126. Van Aubel RA, Smeets PH, van den Heuvel JJ, Russel FG. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol. 2005;288:F327-33. [PMID: 15454390] CrossrefMedlineGoogle Scholar127. Terkeltaub RA, Sklar LA, Mueller H. Neutrophil activation by inflammatory microcrystals of monosodium urate monohydrate utilizes pertussis toxin-insensitive and -sensitive pathways. J Immunol. 1990;144:2719-24. [PMID: 2108211] MedlineGoogle Scholar128. Bomalaski JS, Baker DG, Brophy LM, Clark MA. Monosodium urate crystals stimulate phospholipase A2 enzyme activities and the synthesis of a phospholipase A2-activating protein. J Immunol. 1990;145:3391-7. [PMID: 2230125] MedlineGoogle Scholar129. Gaudry M, Gilbert C, Barabe F, Poubelle PE, Naccache PH. Activation of Lyn is a common element of the stimulation of human neutrophils by soluble and particulate agonists. Blood. 1995;86:3567-74. [PMID: 7579465] CrossrefMedlineGoogle Scholar130. Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkeltaub R. Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum. 2000;43:1145-55. [PMID: 10817569] MedlineGoogle Scholar131. Barabe F, Gilbert C, Liao N, Bourgoin SG, Naccache PH. Crystal-induced neutrophil activation VI. Involvement of FcgammaRIIIB (CD16) and CD11b in response to inflammatory microcrystals. FASEB J. 1998;12:209-20. [PMID: 9472986] CrossrefMedlineGoogle Scholar132. Liu R, Aupperle K, Terkeltaub R. Src family protein tyrosine kinase signaling mediates monosodium urate crystal-induced IL-8 expression by monocytic THP-1 cells. J Leukoc Biol. 2001;70:961-8. [PMID: 11739559] MedlineGoogle Scholar133. Terkeltaub R, Zachariae C, Santoro D, Martin J, Peveri P, Matsushima K. Monocyte-derived neutrophil chemotactic factor/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum. 1991;34:894-903. [PMID: 2059236] CrossrefMedlineGoogle Scholar134. Schiltz C, Liote F, Prudhommeaux F, Meunier A, Champy R, Callebert J, et al. Monosodium urate monohydrate crystal-induced inflammation in vivo: quantitative histomorphometric analysis of cellular events. Arthritis Rheum. 2002;46:1643-50. [PMID: 12115197] CrossrefMedlineGoogle Scholar135. Tramontini NL, Kuipers PJ, Huber CM, Murphy K, Naylor KB, Broady AJ, et al. Modulation of leukocyte recruitment and IL-8 expression by the membrane attack c